Intestinal Dysfunction Treatment via Enzyme and Lipid Mediator Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Conventional treatments for intestinal dysfunction, such as ileus, following surgery or other abdominal conditions, are not directly designed to prevent intestinal motility issues and often result in side effects like discomfort and prolonged recovery.

Innovation Solution

Administering a solution containing digestive enzyme inhibitors, antibiotics, and inflammatory lipid mediator binding proteins into the intestinal lumen and peritoneum to block enzymatic degradation and inflammation, thereby preventing scar tissue formation and preserving intestinal motility.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional adhesion prevention methods (film barriers, sprayable barriers) are used, then organ adhesion is prevented, but intestinal motility is not directly improved and recovery time is prolonged

Engineering Contradiction:

Improveadhesion preventionVSAvoidrecovery time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The treatment is divided into multiple components administered at different times and locations: digestive enzyme inhibitors given orally or by nasogastric tube before and after surgery, antibiotics administered systemically, and inflammatory lipid mediator binding proteins applied topically to the intestinal surface. This segmented approach addresses different aspects of ileus pathogenesis simultaneously, improving both adhesion prevention and motility recovery faster than single-agent conventional barriers.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

Digestive enzyme inhibitors are administered before surgery (preoperatively) and continued after surgery, and antibiotics are started before surgical incision. This preliminary action prevents the development of ileus by blocking enzymatic degradation and bacterial translocation before they can occur, rather than treating established adhesion or motility dysfunction.

Inventive Principle:

Principle #10Preliminary action

2Reliability

If bowel rest and nasogastric decompression are used, then intestinal dysfunction is managed, but patient comfort deteriorates and hospital stay is prolonged

Engineering Contradiction:

Improveintestinal dysfunction managementVSAvoidpatient discomfort

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The treatment enables the intestine to recover its own function by blocking the harmful enzymatic and inflammatory processes that cause ileus. As digestive enzyme inhibitors prevent proteolytic degradation and antibiotics control bacterial overgrowth, the intestinal wall and motility mechanisms naturally recover without requiring external mechanical support like nasogastric tubes or forced bowel rest, thereby improving patient comfort.

Inventive Principle:

Principle #25Self-service

3Quantity of substance

If aggressive rehydration is used, then fluid balance is maintained, but intestinal permeability and inflammation are worsened

Engineering Contradiction:

Improvefluid balanceVSAvoidintestinal permeability and inflammation

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

Instead of allowing aggressive rehydration to worsen intestinal permeability and inflammation, the treatment converts this potential harm into benefit by using inflammatory lipid mediator binding proteins to bind and neutralize inflammatory lipids generated during surgery and rehydration. This allows adequate fluid resuscitation to be performed while simultaneously preventing the inflammatory cascade that would otherwise be exacerbated by fluid administration.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach significantly reduces post-surgical complications, shortens recovery time, and minimizes hospital stays by maintaining normal intestinal functions like food transport and fecal production, as demonstrated in rat models.

Implementation Method 1

Administering a solution containing digestive enzyme inhibitors, antibiotics, and inflammatory lipid mediator binding proteins into the intestinal lumen and peritoneum to block enzymatic degradation

Methodology Applied

Scientific EffectEnzyme inhibition: Enzyme

Implementation Method 2

inflammatory lipid mediator binding proteins into the intestinal lumen and peritoneum to block enzymatic degradation and inflammation

Methodology Applied

Scientific EffectLipid binding: Absorption (physical)

Data Source

PatentUS9962432B2Minimizing intestinal dysfunction

Publication Date: 2018.05.08 RGT UNIV OF CALIFORNIA

AI summary

Techniques are disclosed for treating or reducing symptoms associated with abdominal dysfunction or ileus following surgery or other abdominal episode by treating the area with a combination of one or more protease, antibacterial compound, and inflammatory lipid mediator.